CATCH AF - Atrial Fibrillation Detection in Cryptogenic Stroke

Brief summary (registry, in English)

Early detection of atrial fibrillation detected after stroke (AFDAS) is crucial for secondary stroke prevention, as initiating direct oral anticoagulants (DOACs) can reduce atrial fibrillation (AF)-related stroke risk by up to 60%. In cryptogenic stroke (CS), AFDAS likely represents the most frequent underlying etiology, yet paroxysmal and short-duration AF episodes often elude standard monitoring. The Graz AF Risk Score, implemented across all Neurology Departments in Styria, Austria, stratifies patients into tailored monitoring pathways but remains limited by delays in implantable loop recorder (ILR) implantation, patient refusal, and restricted access to early ambulatory ECG monitoring. The study aims to close diagnostic gaps in the current AF detection pathway by implementing a non-invasive, wrist-worn photoplethysmography (PPG) device (i.e., CardioWatch 287-2 \[CW2\]) for early cardiac rhythm monitoring in CS patients. Methods: CATCH-AF is an investigator-initiated, prospective, longitudinal, multi-center, pre-post interventional study including all CS patients admitted to one of five Styrian Neurology Departments. In the pre-intervention phase, AF detection will follow the established Graz AF Risk Score-based algorithm. In the intervention phase, CardioWatch 287-2 screening will replace Holter-ECG screening in moderate-risk patients and will be used for high-risk patients with delayed or declined ILR implantation. Suspected AF episodes will be confirmed by ECG- based assessment at the discretion of the treating cardiologist. The primary endpoint isAFDAS detection at 3 months; secondary endpoints include AFDAS at 12 months, time to AF detection and DOAC initiation, cerebrovascular event recurrence, cardiovascular death, and all-cause mortality at 3 and 12 months. Data will be collected via REDCap and analyzed using descriptive, univariable, and multivariable regression methods, adjusted for confounders with inverse probability of treatment weighting. The investigators hypothesize that CardioWatch 287-2 implementation will increase early AFDAS detection and reduce diagnostic and therapeutic delays, potentially lowering recurrent cerebrovascular events and mortality over 12 months. CATCH-AF represents the first European, population-wide evaluation of a wrist-worn PPG device integrated into an established AF detection pathway for cryptogenic stroke, aiming to improve early diagnosis, treatment initiation and secondary prevention outcomes.

What you commit to

• Study type: Interventional
• Planned participants: 1500
• From 1 Oct 2026 to the primary completion date, 31 Aug 2029
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.